Last reviewed · How we verify

Ad26.ZEBOV, MVA-BN-Filo vaccine

London School of Hygiene and Tropical Medicine · Phase 3 active Biologic

Ad26.ZEBOV, MVA-BN-Filo vaccine is a Viral vector vaccine Biologic drug developed by London School of Hygiene and Tropical Medicine. It is currently in Phase 3 development for Prevention of Ebola virus disease (Zaire ebolavirus).

A two-dose heterologous prime-boost vaccine regimen that uses recombinant adenovirus 26 (Ad26) and modified vaccinia Ankara (MVA) vectors expressing Ebola virus glycoprotein to elicit cellular and humoral immune responses against Ebola virus.

A two-dose heterologous prime-boost vaccine regimen that uses recombinant adenovirus 26 (Ad26) and modified vaccinia Ankara (MVA) vectors expressing Ebola virus glycoprotein to elicit cellular and humoral immune responses against Ebola virus. Used for Prevention of Ebola virus disease (Zaire ebolavirus).

At a glance

Generic nameAd26.ZEBOV, MVA-BN-Filo vaccine
SponsorLondon School of Hygiene and Tropical Medicine
Drug classViral vector vaccine
TargetEbola virus glycoprotein (ZEBOV)
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease
PhasePhase 3

Mechanism of action

The Ad26.ZEBOV vaccine primes the immune system with an adenovirus-vectored Ebola glycoprotein, followed by an MVA-vectored boost to enhance and broaden the immune response. This heterologous prime-boost strategy leverages two different viral vectors to maximize T-cell and antibody responses against Ebola virus, providing durable protection against infection.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Ad26.ZEBOV, MVA-BN-Filo vaccine

What is Ad26.ZEBOV, MVA-BN-Filo vaccine?

Ad26.ZEBOV, MVA-BN-Filo vaccine is a Viral vector vaccine drug developed by London School of Hygiene and Tropical Medicine, indicated for Prevention of Ebola virus disease (Zaire ebolavirus).

How does Ad26.ZEBOV, MVA-BN-Filo vaccine work?

A two-dose heterologous prime-boost vaccine regimen that uses recombinant adenovirus 26 (Ad26) and modified vaccinia Ankara (MVA) vectors expressing Ebola virus glycoprotein to elicit cellular and humoral immune responses against Ebola virus.

What is Ad26.ZEBOV, MVA-BN-Filo vaccine used for?

Ad26.ZEBOV, MVA-BN-Filo vaccine is indicated for Prevention of Ebola virus disease (Zaire ebolavirus).

Who makes Ad26.ZEBOV, MVA-BN-Filo vaccine?

Ad26.ZEBOV, MVA-BN-Filo vaccine is developed by London School of Hygiene and Tropical Medicine (see full London School of Hygiene and Tropical Medicine pipeline at /company/london-school-of-hygiene-and-tropical-medicine).

What drug class is Ad26.ZEBOV, MVA-BN-Filo vaccine in?

Ad26.ZEBOV, MVA-BN-Filo vaccine belongs to the Viral vector vaccine class. See all Viral vector vaccine drugs at /class/viral-vector-vaccine.

What development phase is Ad26.ZEBOV, MVA-BN-Filo vaccine in?

Ad26.ZEBOV, MVA-BN-Filo vaccine is in Phase 3.

What are the side effects of Ad26.ZEBOV, MVA-BN-Filo vaccine?

Common side effects of Ad26.ZEBOV, MVA-BN-Filo vaccine include Injection site pain or erythema, Fatigue, Myalgia, Headache, Fever.

What does Ad26.ZEBOV, MVA-BN-Filo vaccine target?

Ad26.ZEBOV, MVA-BN-Filo vaccine targets Ebola virus glycoprotein (ZEBOV) and is a Viral vector vaccine.

Related